Bridging the innate to adaptive immune response
Highlight (ex Bioncotech) is a clinical-stage, immune-oncology company focused on developing a cutting-edge RNA-based therapies against validated and novel targets in cancer and immune cells.
CEO Marisol Quintero
Advent Contact Shahzad Malik
Private Companies
Highlight Therapeutics announces follow-up results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at AACR
Press Release. BO-112 demonstrates potential as new and highly effective second line therapy for melanoma BO-112 demonstrates potential as best-in-class therapy to overcome anti-PD1 resistance in melanoma patients whose…
Read More
Highlight Therapeutics to present at the American Association for Cancer Research (AACR) Annual Meeting 2022
Press Release. Final results of SPOTLIGHT203 phase 2 study demonstrate new approach to second line treatment for melanomaMadrid, Spain, 15 March, 2022 – Highlight Therapeutics, (“Highlight”), a clinical-stage biopharmaceutical…
Read More
Highlight Therapeutics & Cima announce positive results from pre-clinical study combining BO-112 + STING agonist published in Journal for ImmunoTherapy of Cancer
Press Release. Intratumoral co-injection of BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy Pre-clinical study data follow publication of positive Phase 2 results of…
Read More
Highlight Therapeutics announces positive preliminary results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at SITC
Press Release. Highlight Therapeutics announces positive preliminary results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at SITC Breakthrough cancer treatment shows best-in-class…
Read More
Highlight Therapeutics to present data from Phase 2 immunotherapy studies of liver metastases and melanoma data at AACR Virtual Annual Meeting 202
Press Release. Madrid, Spain, 14 April, 2021 – Highlight Therapeutics, (“Highlight”), a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, today announced that data from Phase 2 studies of…
Read More
Highlight Therapeutics and Pivotal work together on Melanoma therapy and launch a Phase IIa trial to examine BO-112 efficacy and safety
Press Release. Trial will examine administration of Highlight’s BO-112 in combination with an anti-PD1 in unresectable or metastatic melanoma patients Recruitment has already begun across 19 top-level centers in…
Read More
Highlight Therapeutics announces first patient dosed in Phase IIa study in liver metastasis
Press Release. Second collaboration with MSD to evaluate combination of BO-112 and KEYTRUDA® • New research studies may further accelerate delivery of novel treatment strategies for melanoma Madrid, Spain…
Read More
Highlight Therapeutics appoints Dr. Carlos Paya as Executive Chairman
Press Release. Dr Ralph Weichselbaum, Dr.Antoni Ribas & Michael Docherty appointed to SAB Company renamed to Highlight Therapeutics Madrid, Spain –April 17, 2020: Highlight Therapeutics (“Highlight”), a clinical-stagebio pharmaceutical…
Read More
Highlight Therapeutics announces name change from Bioncotech and launch of new website
Press Release. Madrid, Spain –April 17, 2020:Highlight Therapeutics, a clinical-stagebio pharmaceutical company developing RNA-based therapies against cancer, announces that it has changed its name from Bioncotech with immediate effect.…
Read More
